A61K 48/0025
Wherein the non-active part clearly interacts with the delivered nucleic acid
Official title: {wherein the non-active part clearly interacts with the delivered nucleic acid}
A61K48/0025 (Wherein the non-active part clearly interacts with the delivered nucleic acid) appears on 927 US grants and 2,584 published applications in this corpus.
Search patents in A61K- Granted patents
- 927
- Published applications
- 2,584
- Assignees
- 917
- Inventors
- 4,999
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 5 | 4 |
| 2002 | 12 | 19 |
| 2003 | 8 | 44 |
| 2004 | 11 | 45 |
| 2005 | 15 | 40 |
| 2006 | 15 | 50 |
| 2007 | 8 | 27 |
| 2008 | 13 | 32 |
| 2009 | 12 | 30 |
| 2010 | 18 | 44 |
| 2011 | 16 | 43 |
| 2012 | 18 | 33 |
| 2013 | 24 | 61 |
| 2014 | 36 | 77 |
| 2015 | 41 | 69 |
| 2016 | 47 | 76 |
| 2017 | 45 | 62 |
| 2018 | 41 | 93 |
| 2019 | 59 | 99 |
| 2020 | 54 | 101 |
| 2021 | 47 | 118 |
| 2022 | 57 | 157 |
| 2023 | 79 | 230 |
| 2024 | 63 | 353 |
| 2025 | 93 | 359 |
| 2026 | 84 | 318 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- Cationic lipid having disulfide bond, lipid membrane structure including same, nucleic acid introduction agent and pharmaceutical composition containing any one of same, method for introducing nucleic acid into cell or target cell, and method for producing cellular pharmaceutical29 Sep 2026US 12,746,202 B2National University Corporation Chiba University
- Methods of producing microbubble drug conjugates, viral gene therapy microbubble conjugates and targeted microbubbles29 Sep 2026US 12,746,292 B2
- DNA vector delivery using lipid nanoparticles29 Sep 2026US 12,746,293 B2NanoVision Therapeutics Inc.
- Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene29 Sep 2026US 12,747,430 B2Precision BioSciences, Inc.
- Methods and materials for treating cancer8 Oct 2026US 2026/0306630 A1Mayo Foundation for Medical Education and Research
- Capsids and methods of targeting neurons8 Oct 2026US 2026/0306661 A1Capsigen Inc.
- Molecular-genetic strategy for the reactivation of juvenile plasticity in targeted adult neural circuits8 Oct 2026US 2026/0306662 A1The Regents of the University of California
- Formulations comprising recombinant aav and methods of administering the same8 Oct 2026US 2026/0306663 A1Ultragenyx Pharmaceutical Inc.
- Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies8 Oct 2026US 2026/0306664 A1AbbVie Inc.
Most cited
By later US patents
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Lipid formulations for nucleic acid delivery334US 8,058,069 B2Protiva Biotherapeutics, Inc. · 2011
- Cationic lipids and methods of use267US 7,745,651 B2Protiva Biotherapeutics, Inc. · 2010
- RNA containing modified nucleosides and methods of use thereof230US 8,691,966 B2The Trustees of the University of Pennsylvania · 2014